Cargando…

Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)

BACKGROUND: PCSK9 regulates low-density lipoprotein cholesterol (LDLc) level and has been implicated in hypercholesterolemia. Aberrant plasma lipid profile is often associated with various cancers. Clinically, the relationship between altered serum lipid level and hepatocellular carcinoma (HCC) has...

Descripción completa

Detalles Bibliográficos
Autores principales: Athavale, Dipti, Chouhan, Surbhi, Pandey, Vimal, Mayengbam, Shyamananda Singh, Singh, Snahlata, Bhat, Manoj Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201570/
https://www.ncbi.nlm.nih.gov/pubmed/30386595
http://dx.doi.org/10.1186/s40170-018-0187-2
_version_ 1783365532312928256
author Athavale, Dipti
Chouhan, Surbhi
Pandey, Vimal
Mayengbam, Shyamananda Singh
Singh, Snahlata
Bhat, Manoj Kumar
author_facet Athavale, Dipti
Chouhan, Surbhi
Pandey, Vimal
Mayengbam, Shyamananda Singh
Singh, Snahlata
Bhat, Manoj Kumar
author_sort Athavale, Dipti
collection PubMed
description BACKGROUND: PCSK9 regulates low-density lipoprotein cholesterol (LDLc) level and has been implicated in hypercholesterolemia. Aberrant plasma lipid profile is often associated with various cancers. Clinically, the relationship between altered serum lipid level and hepatocellular carcinoma (HCC) has been documented; however, the underlying cause and implications of such dyslipidemia remain unclear. METHODS: The present study includes the use of HepG2 tumor xenograft model to study the potential role of glucose (by providing 15% glucose via drinking water) in regulating PCSK9 expression and associated hypercholesterolemia. To support in vivo findings, in vitro approaches were used by incubating HCC cells in culture medium with different glucose concentrations or treating the cells with glucose uptake inhibitors. Impact of hypercholesterolemia on chemotherapy was demonstrated by exogenously providing LDLc followed by appropriate in vitro assays. RESULTS: We observed that serum and hepatic PCSK9 level is decreased in mice which were provided with glucose containing water. Interestingly, serum and tumor PCSK9 level was upregulated in HepG2-tumor-bearing mice having access to water containing glucose. Additionally, elevated LDLc is detected in sera of these mice. In vitro studies indicated that PCSK9 expression was increased by high glucose availability with potential involvement of reactive oxygen species (ROS) and sterol regulatory element binding protein-1 (SREBP-1). Furthermore, it is also demonstrated that pre-treatment of cells with LDLc diminishes cytotoxicity of sorafenib in HCC cells. CONCLUSION: Taken together, these results suggest a regulation of PCSK9 by high glucose which could contribute, at least partly, towards understanding the cause of hypercholesterolemia in HCC and its accompanied upshots in terms of altered response of HCC cells towards cancer therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40170-018-0187-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6201570
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62015702018-10-31 Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9) Athavale, Dipti Chouhan, Surbhi Pandey, Vimal Mayengbam, Shyamananda Singh Singh, Snahlata Bhat, Manoj Kumar Cancer Metab Research BACKGROUND: PCSK9 regulates low-density lipoprotein cholesterol (LDLc) level and has been implicated in hypercholesterolemia. Aberrant plasma lipid profile is often associated with various cancers. Clinically, the relationship between altered serum lipid level and hepatocellular carcinoma (HCC) has been documented; however, the underlying cause and implications of such dyslipidemia remain unclear. METHODS: The present study includes the use of HepG2 tumor xenograft model to study the potential role of glucose (by providing 15% glucose via drinking water) in regulating PCSK9 expression and associated hypercholesterolemia. To support in vivo findings, in vitro approaches were used by incubating HCC cells in culture medium with different glucose concentrations or treating the cells with glucose uptake inhibitors. Impact of hypercholesterolemia on chemotherapy was demonstrated by exogenously providing LDLc followed by appropriate in vitro assays. RESULTS: We observed that serum and hepatic PCSK9 level is decreased in mice which were provided with glucose containing water. Interestingly, serum and tumor PCSK9 level was upregulated in HepG2-tumor-bearing mice having access to water containing glucose. Additionally, elevated LDLc is detected in sera of these mice. In vitro studies indicated that PCSK9 expression was increased by high glucose availability with potential involvement of reactive oxygen species (ROS) and sterol regulatory element binding protein-1 (SREBP-1). Furthermore, it is also demonstrated that pre-treatment of cells with LDLc diminishes cytotoxicity of sorafenib in HCC cells. CONCLUSION: Taken together, these results suggest a regulation of PCSK9 by high glucose which could contribute, at least partly, towards understanding the cause of hypercholesterolemia in HCC and its accompanied upshots in terms of altered response of HCC cells towards cancer therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40170-018-0187-2) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-25 /pmc/articles/PMC6201570/ /pubmed/30386595 http://dx.doi.org/10.1186/s40170-018-0187-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Athavale, Dipti
Chouhan, Surbhi
Pandey, Vimal
Mayengbam, Shyamananda Singh
Singh, Snahlata
Bhat, Manoj Kumar
Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
title Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
title_full Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
title_fullStr Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
title_full_unstemmed Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
title_short Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9)
title_sort hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (pcsk9)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201570/
https://www.ncbi.nlm.nih.gov/pubmed/30386595
http://dx.doi.org/10.1186/s40170-018-0187-2
work_keys_str_mv AT athavaledipti hepatocellularcarcinomaassociatedhypercholesterolemiainvolvementofproproteinconvertasesubtilisinkexintype9pcsk9
AT chouhansurbhi hepatocellularcarcinomaassociatedhypercholesterolemiainvolvementofproproteinconvertasesubtilisinkexintype9pcsk9
AT pandeyvimal hepatocellularcarcinomaassociatedhypercholesterolemiainvolvementofproproteinconvertasesubtilisinkexintype9pcsk9
AT mayengbamshyamanandasingh hepatocellularcarcinomaassociatedhypercholesterolemiainvolvementofproproteinconvertasesubtilisinkexintype9pcsk9
AT singhsnahlata hepatocellularcarcinomaassociatedhypercholesterolemiainvolvementofproproteinconvertasesubtilisinkexintype9pcsk9
AT bhatmanojkumar hepatocellularcarcinomaassociatedhypercholesterolemiainvolvementofproproteinconvertasesubtilisinkexintype9pcsk9